Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
EyePoint Pharmaceuticals Inc
EYPT
Healthcare
Biotechnology
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment...
for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company’s other products include YUTIQ, and DEXYCU.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:EYPT)
New Post
View:
Posts & Comments
Threaded Posts
(282)
•••
whytestocks
X
Post by
whytestocks
on Oct 28, 2024 1:16pm
EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) Near the Top of
Just In: $EYPT EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) Near the Top of Equities by Percentage Gain on 10/28EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is one of today's top gainers. The
...more
(282)
•••
whytestocks
X
Post by
whytestocks
on May 06, 2024 5:30pm
Spirit Airlines Posts Weak Results, Joins Integra LifeScienc
JUST IN: $EYPT Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving Lower On Monday | BenzingaU.S. stocks were higher, with the Nasdaq Composite gaining
...more
(282)
•••
whytestocks
X
Post by
whytestocks
on Jan 31, 2024 3:00pm
EyePoint Pharmaceuticals to Present at the Guggenheim Health
Breaking News: $EYPT EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceWATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint
...more
(0)
•••
PumperGuy
X
Post by
PumperGuy
on Jan 22, 2024 5:40pm
I "SEE" nothing but $$$$$$$ Coming our way!
Here's to LOOKING up!!
(4)
•••
AviseAnalytics
X
Post by
AviseAnalytics
on Jan 05, 2024 8:10am
EYEPOINT PHARMACEUTICALS: A BOON FOR EYE DISEASE PATIENTS
$EYPT Excited to share an article about EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) - the Company develops and commercializes therapeutics to improve the lives of patients with severe eye disorders.
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Q Precious & Battery Metals To Resume Diamond Drilling La Corne South Project, Val D'or Quebec
Do you want to stay ahead of the markets? See how DealRoom can help.
Why Dozens of Pro Athletes are Paying Attention to this Product